Search results for " market" in Articles / App Notes
Article
A Second Modular Biopharma Facility Opens: KUBio in Hangzhou
To bring advanced biosimilar products to the Chinese market quickly, Pfizer’s Global Biotechnology Center will make use of Cytiva’s KUBio advanced modular manufacturing solution. KUBio modules …
Article
Downstream Processing Continues to Worry CMOs
Single-use devices to the rescue?
To get a better sense of how the biopharmaceutical manufacturing market is positioning itself to deal with these problems, respondents were asked to identify acti…
Article
Continuous Processing for the Production of Biopharmaceuticals
While there is a plethora of emerging continuous bioprocessing technologies available in the market, there are almost no concrete examples of successful implementation and integration of a fully conti…
Article
Antibody Production in Microbial Hosts
With more than 200 recombinant proteins on the market today, the biopharmaceutical industry is expected to reach approximately $180 billion by 2016 (1). Therapeutic mAbs and their derivatives—such as …
Article
Selecting the Right Viral Clearance Technology
Filter manufacturers are working to address these issues, and Riske looks forward to seeing solutions on the market in the future. Another important development for the biopharmaceutical industry has …
Article
Automated harvesting and 2-step purification of unclarified mammalian cell-culture broths containing antibodies
Therapeutic monoclonal antibodies represent one of the fastest growing segments in the pharmaceutical market. The growth of the segment has necessitated development of new efficient and cost saving …
Article
Applications of Surface Plasmon Resonance for Detection of Bispecific Antibody Activity
Manufacturing and quality control helps ensure the supply of a consistent quality product to the market. CQAs are determined using the “best” knowledge at a given time; they may later have to be revis…
Article
Risk Assessment and Mitigation in Biopharmaceutical Manufacturing
Some of the reasons leading to supply shortages could be increased market demand, poor product quality and/or GMP practice, increasing regulatory expectations, or limited or competing manufacturing ca…
Article
USP Stresses Pharmacopeial Standards at CPhI China
The USP requirements for elemental impurities, FDA’s metrics program, and the generic-drug market were also discussed.
USP stressed the need for compliance with global regulations and standards du…
Article
What’s In a Name? For Biosimilars, A Lot
International Nonproprietary Names (INNs) are given to most drugs early in the drug-development process, even though many of these drugs never make it onto the market. The INN is established by the Wo…